Sec. 3057. CLIA waiver improvements
133 words·~1 min read·
/bill/114/hr/34/enr/section-3057·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall publish a draft guidance that— revises Section V. Demonstrating Insignificant Risk of an Erroneous Result – Accuracy of the guidance entitled Recommendations for Clinical Laboratory Improvement Amendments of 1988
(CLIA)Waiver Applications for Manufacturers of In Vitro Diagnostic Devices and dated January 30, 2008; and includes the appropriate use of comparable performance between a waived user and a moderately complex laboratory user to demonstrate accuracy. The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall finalize the draft guidance published under subsection
(a)not later than 1 year after the comment period for such draft guidance closes.